Author + information
- Fei Chen,
- Fan Liu and
- Wei Cui
This study sought to investigate the preventive effect of atorvastatin(ATO) combined with trimetazidine(TMZ) on contrast-induced nephropathy(CIN) in patients with diabetes mellitus undergoing elective percutaneous coronary intervention(PCI).
165 patients with type 2 diabetes mellitus who were undergoing elective PCI were randomly assigned to ATO plus TMZ group(n=82) and control group(n=83). In ATO plus TMZ group, ATO was administered pre-PCI 24 hours 80mg and post-PCI 40mg/day for 72 hours, TMZ was administered 20mg thrice daily for 48 hours pre-PCI and 24 hours post-PCI. All patients had basic atorvastatin treatment(20mg/day) and standard hydration. Serum creatinine (SCr), cystatin (CysC) and high sensitive-C-reactive protein(hs-CRP) were detected before and after contrast media injection, and the incidence of CIN was evaluated according to the elevation of SCr. Adverse events were observed in 30 days.
Baseline characteristics of the patients in the two groups were similar. Compared with the control group, ATO+TMZ group tended to have a lower SCr, Cys-C and hs-CRP levels at 48h after the procedure (all P < 0.05). The incidence of CIN was significantly lower in ATO+TMZ group compared with control group (4.89 vs. 15.66%, P = 0.023). There was no difference about the incidence of adverse events within 30 days between ATO+TMZ group and control group (3.66 vs. 7.23%, P=0.313).
ATO combined with TMZ is more effective in prevention of CIN and kidney protection in patients with diabetes mellitus undergoing elective percutaneous coronary intervention(PCI).